Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Mesoblast reports FY2026 profitability; major Phase 3 readouts and expansions ahead

Aug 26, 2026, 8:35 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The results show improved profitability trajectory alongside strong RYONCIL adoption, expanding TAM via adult SR-aGvHD labeling and a pivotal CLBP readout, plus favorable financing. These catalysts can drive revaluation despite ongoing losses, especially given mid-2027 topline potential and a multi-billion TAM claim for rexlemestrocel-L.

AI summary

What happened, with direct paths to the underlying reporting

Mesoblast reports FY2026 gross profit of $103.6M on $120.3M revenue, with U.S. RYONCIL adoption boosting net revenue to $115.2M. The company plans label expansion to adults with SR-aGVHD and accelerates rexlemestrocel-L Phase 3 for chronic low back pain, with top-line readout due mid-CY2027, potentially unlocking a multi-billion-dollar market. Cash stands at $103M, plus a $125M five-year credit line.

FY2026 revenue $120.3M; gross profit $103.6M.
Ryoncil U.S. launch net revenue $115.2M; gross-to-net 13.4%.
Rexlemestrocel-L Phase 3 for CLBP: 350 patients treated; readout mid-CY2027.
Adults SR-aGvHD label expansion; Duchenne trial IND clearance.
Ending cash $103M; $125M five-year non-dilutive credit line.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.